AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Global Amyotrophic Lateral Sclerosis Treatment Market 2019-2023| Evolving Opportunities with ITALFARMACO & Mitsubishi Tanabe Pharma |Technavio

November 22, 2019 GMT
Global Amyotrophic Lateral Sclerosis Treatment Market 2019-2023| Evolving Opportunities with ITALFARMACO & Mitsubishi Tanabe Pharma |Technavio
Global Amyotrophic Lateral Sclerosis Treatment Market 2019-2023| Evolving Opportunities with ITALFARMACO & Mitsubishi Tanabe Pharma |Technavio

LONDON--(BUSINESS WIRE)--Nov 22, 2019--

The global amyotrophic lateral sclerosis (ALS) treatment market size is poised to grow by USD 491.29 million during 2019-2023, according to a new report by Technavio, progressing at a CAGR of close to 20% during the forecast period. Request Free Sample Pages

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191122005344/en/

Technavio has announced its latest market research report titled global amyotrophic lateral sclerosis treatment market 2019-2023 (Graphic: Business Wire)

Read the 116-page research report with TOC on “Amyotrophic Lateral Sclerosis Treatment Market Analysis Report by Type (Intravenous and Oral) and Geography (Americas, APAC, and EMEA) 2019-2023.

The market is driven by the increase in the incidence and prevalence of ALS. Also, the development of novel approaches for the treatment of amyotrophic lateral sclerosis are anticipated to further boost the growth of the amyotrophic lateral sclerosis treatment market.

The prevalence of amyotrophic lateral sclerosis has been increasing. In the US, the incidence of amyotrophic lateral sclerosis cases was estimated to be 3.9 per 100,000 people during 2010-2011. In 2014, this figure rose to 5.0 per 100,000 persons. Amyotrophic lateral sclerosis is more common among white men, non-Hispanics, and individuals between aged 60-69 years in the US. Thus, with the increase in the prevalence of ALS, the market is expected to witness accelerated growth during the forecast period.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Major Four Amyotrophic Lateral Sclerosis Treatment Companies:

ITALFARMACO

ITALFARMACO manufactures and distributes pharmaceutical products worldwide. The company produces prefilled syringes, sterilized ampoules, injectables, and liquid oral drugs. The company’s key offerings include TIGLUTIK, which is a prescription medicine for the treatment of amyotrophic lateral sclerosis.

Mitsubishi Tanabe Pharma

Mitsubishi Tanabe Pharma operates the business under the segment, Pharmaceuticals. The segment includes therapeutic areas such as autoimmune, diabetes, kidney, and central nervous system. The company’s key offerings include Radicava, which is an intravenous medication that is used to treat amyotrophic lateral sclerosis.

Sanofi

Sanofi has business operations under various segments, which include pharmaceuticals, vaccines, and consumer healthcare. The company’s key offerings include Rilutek, which is used to treat amyotrophic lateral sclerosis. The drug falls under the benzothiazole class.

Pfizer

Pfizer operates as a pharmaceutical company and offers vaccines, medicines, medical devices, and consumer healthcare products for inflammation, cardiovascular diseases, oncology, and other therapeutic areas. In Jan 2018, Pfizer partnered with Sangamo Therapeutics to develop a potential gene therapy for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD).

Omega Protein Corporation

Omega Protein Corporation operates the business through various segments, which include human nutrition, animal nutrition, and science and innovation. The company offers plant-based proteins under the brand name Bioriginal.

Register for a free trial today and gain instant access to 17,000+ market research reports. Technavio’s SUBSCRIPTION platform

Amyotrophic Lateral Sclerosis Treatment Type Outlook (Revenue, USD Million, 2019-2023)

  • Intravenous
  • Oral

Amyotrophic lateral sclerosis treatment Regional Outlook (Revenue, USD Million, 2019-2023)

  • Americas
  • APAC
  • EMEA

Technavio’s sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more.Request a free sample report

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20191122005344/en/

CONTACT: Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

Email:media@technavio.com.

Website:https://www.technavio.com/

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Technavio Research

Copyright Business Wire 2019.

PUB: 11/22/2019 02:30 PM/DISC: 11/22/2019 02:30 PM

http://www.businesswire.com/news/home/20191122005344/en